Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC.

@article{Fiala2017SerumCO,
  title={Serum Concentration of Erlotinib and its Correlation with Outcome and Toxicity in Patients with Advanced-stage NSCLC.},
  author={Ondrej Fiala and Petr Hosek and Milo{\vs} Pe{\vs}ek and Jindrich Finek and Jaroslav R{\'a}cek and Pavel Stehl{\'i}k and Ondřej {\vS}orejs and Marek Minarik and Lucie Benesova and Adam Celer and Ivana Nemcova and Radek Kucera and Ondřej Topol{\vc}an},
  journal={Anticancer research},
  year={2017},
  volume={37 11},
  pages={6469-6476}
}
BACKGROUND Erlotinib is a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR); it is used in the treatment of advanced non-small cell lung cancer (NSCLC). We focused on the role of serum concentration of erlotinib and its association with outcome and toxicity in patients with advanced NSCLC harbouring the wild-type EGFR gene or squamous histology. PATIENTS AND METHODS Clinical data of 122 patients were analyzed. Serum samples were collected within four weeks after the… CONTINUE READING

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…